ライフサイエンスコーパス: desferrioxamine

1 nthesis (5-fluorouracil), or sequester iron (desferrioxamine).

2 iii)-hydroxide sucrose) or an iron chelator (desferrioxamine).

3 ructurally unrelated chelators dipyridyl and desferrioxamine.

4 ponsive to intracellular iron chelation with desferrioxamine.

5 ontrols who were on long-term treatment with desferrioxamine.

6 by hypoxia and the hypoxia mimics cobalt and desferrioxamine.

7 either cobalt chloride or the iron chelator desferrioxamine.

8 d are either hypoxic or have been exposed to desferrioxamine.

9 henylphenylenediamine, and the iron chelator desferrioxamine.

10 hich is also inducible by the iron chelator, desferrioxamine.

11 ere also induced by exposure of the cells to desferrioxamine.

12 f the inducible response to both hypoxia and desferrioxamine.

13 factor beta (TGF-beta) and the hypoxia mimic desferrioxamine.

14 Lysosomal iron chelation was achieved with desferrioxamine.

15 cally decreased RAGE induction by hypoxia or desferrioxamine.

16 tection was not observed with iron-saturated desferrioxamine.

17 The iron chelator desferrioxamine (100 microM) in vitro prevented the amin

18 (30 and 100 U ml-1), or by the iron chelator desferrioxamine (100 microM).

19 O(2), 5% CO(2), and 94% N(2)) or chemically (desferrioxamine; 250 muM)-induced hypoxia followed by de

20 l body radiation exposure relative to (89)Zr-desferrioxamine-5B1.

21 rotocol involved treatment of the cells with desferrioxamine, a cell-permeant, Fe(III)-specific chela

22 f intracellular iron-dependent peroxidation, desferrioxamine, abolished the elevation in cellular ROS

23 Chelation of iron by desferrioxamine abrogates the antiparasitic activity of

24 rioxamine: like hypoxia, cobalt chloride and desferrioxamine activate hypoxia-inducible factor 1alpha

25 Moreover, cobalt chloride and desferrioxamine activated HIF-1 but not IAP-2.

26 Pretreatment of astrocytes with desferrioxamine also did not induce the inhibition of T.

27 Co2+ and desferrioxamine also increased VEGF levels, while inhibi

28 n, treatment of cells with the iron chelator desferrioxamine also reduced MLH1 and PMS2 levels, in ke

29 Desferrioxamine, an avid iron chelator, had no effect on

30 plates that are homogenized and treated with desferrioxamine, an Fe(III) chelator, prior to packing t

31 a-3 PUFA, cotreatment with the iron chelator desferrioxamine, an inhibitor of iron-dependent lipid pe

32 MEL cells, expression of TfR1 was induced by desferrioxamine, an iron chelator, and it was reduced by

33 o inhibited significantly in the presence of desferrioxamine, an iron chelator, but this protection w

34 mparable to synthetic metal chelating agents desferrioxamine and clioquinol.

35 The iron chelators desferrioxamine and cobalt chloride, which induce hypoxi

36 generation correlated positively with use of desferrioxamine and deferriprone respectively (two studi

37 Competition of Arctic Fe-HS complexes with desferrioxamine and EDTA indicated that their stability

38 B (FatB), PB (FpuA), schizokinen (YfiY), and desferrioxamine and ferrichrome (YxeB).

39 m/z signals for Th-hydroxamate siderophore (desferrioxamine and ferrichrome) complexes, with Th comp

40 Desferrioxamine and hypoxia were also able to suppress t

41 UTR is reduced after treatment of cells with desferrioxamine and increased after interleukin-1 stimul

42 alternatively labeled with (124)I- or (89)Zr-desferrioxamine and injected into mice bearing either ma

43 igands binding to the oxygen sensor, whereas desferrioxamine and perhaps cobalt appear to act at a si

44 ence of transition metal chelators (DTPA +/- desferrioxamine), and was inhibited by catalase, superox

45 ; DFO-squaramide; DFO*-Bz-NCS, where DFO* is desferrioxamine*; and DFO*-squaramide).

46 Iron chelators, such as EDTA, desferrioxamine, and deferiprone, were found to cause th

47 2C12 cells to dimethyl oxalylglycine (DMOG), desferrioxamine, and hypoxia, all inhibitors of prolyl h

48 Normoxic inducers of HIF (CoCl(2), desferrioxamine, and l-mimosine) and 100 ng/ml ANGPTL4 s

49 r doses, in combination with the older agent desferrioxamine, and recent trials' data have shown effi

50 The presence of the siderophore desferrioxamine B (a strong Mn(III)-complexing ligand) e

51 ises an iron-specific chelating biomolecule, desferrioxamine B (DFB), covalently immobilized on a mes

52 xperiments with the strong Mn(III) chelator, desferrioxamine B (DFB), in seawater indicated that the

53 quantification of mAbs, after chelation with desferrioxamine B (DFO) and radiolabeling with (89)Zr, h

54 ing of monoclonal antibodies conjugated with desferrioxamine B (DFO), describes its effects on radiop

55 preparation and in vivo evaluation of (89)Zr-desferrioxamine B (DFO)-7E11, a novel (89)Zr-labeled mon

56 ning (89)Zr-oxalate, the photoactive chelate desferrioxamine B (DFO)-aryl azide (DFO-ArN(3)), and Met

57 t study, we report the preparation of (89)Zr-desferrioxamine B (DFO)-J591, a novel (89)Zr-labeled mon

58 eB binds ferrioxamine B (FO, Fe-siderophore)/desferrioxamine B (DFO, apo-siderophore) in vitro.

59 nts using two structurally distinct ligands (desferrioxamine B (DFOB) and N, N'-di(2-hydroxybenzyl)et

60 by examining the effects of the siderophore desferrioxamine B (DFOB) on Fe removal from aquatic humi

61 ted the potential synergism between ligands (desferrioxamine B (DFOB) or N,N'-Di(2-hydroxybenzyl)ethy

62 udy, catecholate protochelin and hydroxamate desferrioxamine B (DFOB) were utilized to examine their

63 lization was found for all ligands examined (desferrioxamine B (DFOB), 2'-deoxymugineic acid (DMA), e

64 tic acid (NTA), iminodiacetic acid (IDA) and desferrioxamine B (DFOB), as well as with Suwannee River

65 The effect of citric acid (CA), desferrioxamine B (DFOB), fulvic acid (FA), and humic ac

66 he presence of a representative siderophore, desferrioxamine B (DFOB), iron (Fe) was released at high

67 igands (2,6-pyridinedicarboxylic acid (DPA), desferrioxamine B (DFOB), N,N'-di(2-hydroxybenzyl)ethyle

68 ylene-diamine-N,N'-diacetic acid (HBED), and desferrioxamine B (DFOB).

69 Mn(III) stabilized by pyrophosphate (PP) and desferrioxamine B (DFOB).

70 A squaramide ester derivative of desferrioxamine B (H(3)DFOSq) was used to prepare four n

71 ovel radiolabeled monoclonal antibody (89)Zr-desferrioxamine B [DFO]-J591 for immuno-PET of prostate-

72 We found that the ferric siderophores desferrioxamine B and aerobactin were not readily bioava

73 nthesis of the WHO-listed essential medicine desferrioxamine B is described.

74 Conjugating the peptide to Desferal (desferrioxamine B mesylate), a chelator in therapeutic u

75 hich redox active iron had been removed with desferrioxamine B prevented all of the gpt- mutations ab

76 Desferrioxamine B was generated over ten linear steps as

77 ions that lanmodulin effectively outcompetes desferrioxamine B, a hydroxamate siderophore previously

78 s complexed with deferoxamine (also known as desferrioxamine B, desferoxamine B), conjugated either t

79 three siderophores of the hydroxamate type: desferrioxamine B, desferrioxamine E, and coelichelin.

80 ), and natural iron binding compounds (e.g., desferrioxamine B, ferrichrome A).

81 ng alcaligin, enterobactin, ferrichrome, and desferrioxamine B.

82 sothiocyanate-DFO [DFO-Bz-NCS], where DFO is desferrioxamine B; DFO-squaramide; DFO*-Bz-NCS, where DF

83 oethite (Gt) in the presence of 20 or 50 muM desferrioxamine-B (DFOB).

84 body trastuzumab, we synthesized a series of desferrioxamine-bearing immunoconjugates with differing

85 splayed distinct localization patterns, with desferrioxamine being confined within the colony area, a

86 ATF3 could also be induced by desferrioxamine but not by the mitochondrial poison cyan

87 assays was stimulated by Ni2+, hypoxia, and desferrioxamine, but this activation was not diminished

88 PASMCs, HIF-1alpha activation by CoCl(2) or desferrioxamine causes DRP1-mediated fission.

89 D9, were radiolabelled with zirconium-89 via desferrioxamine chelation to enable non-invasive molecul

90 Most received desferrioxamine chelation.

91 imaging using (89)Zr-DFO-mAb-B43.13 (DFO is desferrioxamine) clearly delineated CA125-positive OVCAR

92 ze hypoxia inducible factor (HIF), including desferrioxamine, cobalt chloride, and dimethyloxalylglyc

93 common in the deferiprone group than in the desferrioxamine controls (four [27%] vs 20 [67%], p=0.02

94 odds ratio for excess myocardial iron in the desferrioxamine controls versus the deferiprone group wa

95 70% [SD 6.5] vs 63% [6.9], p=0.004) than the desferrioxamine controls.

96 n chelating resin, or the chelators EDTA and desferrioxamine decreased monatin and indole loss for so

97 Exposure to the iron chelator desferrioxamine decreased SPH forming efficiency and the

98 ned three clinically-used chelators, namely, desferrioxamine, deferiprone and deferasirox and compare

99 sponse to the clinically applied medications desferrioxamine, deferiprone, and deferasirox.

100 roxamate siderophores, including three known desferrioxamine derivatives along with 17 new putative a

101 dies indicated that some of the genes in the desferrioxamine (des) and coelichelin (cch) biosynthetic

102 (89)Zr-desferrioxamine (df)-onartuzumab was synthesized using a

103 nm, 220 nm, 1 um, and 6 um-with the chelator desferrioxamine (DFO) and radiolabeled these DFO-bearing

104 Methods: Bexmarilimab was conjugated with desferrioxamine (DFO) and radiolabeled with (89)Zr.

105 Desferrioxamine (DFO) and the hydroxypiridinone (HPO) de

106 Desferrioxamine (DFO) and/or a NIRF dye (FL) were conjug

107 e peptide 1 receptor agonist (GLP-1RA) using desferrioxamine (DFO) as a chelator.

108 n the biosynthesis of the iron overload drug desferrioxamine (DFO) B in Streptomyces coelicolor.

109 Desferrioxamine (DFO) is currently the preferred chelato

110 reptomyces strains produce hydroxamate-based desferrioxamine (DFO) siderophores composed of repeating

111 e hypoxia and the hypoxia mimetics CoCl2 and desferrioxamine (DFO) stabilize it.

112 in response to decreased cellular iron after desferrioxamine (DFO) treatment.

113 rtuzumab was site-specifically modified with desferrioxamine (DFO) via a novel chemoenzymatic strateg

114 An exendin-4 derivative conjugated to desferrioxamine (DFO) was used for radiolabeling with th

115 2 mRNA in K562 cells was not up-regulated by desferrioxamine (DFO), a cell membrane-permeable iron ch

116 monstrated with the classical iron chelator, desferrioxamine (DFO), and was not observed for the DFO-

117 Here, we reveal how the iron-binding ligands desferrioxamine (DFO), di-2-pyridylketone-4,4-dimethyl-3

118 Here, we evaluated [(89)Zr]Zr-desferrioxamine (DFO)-daratumumab PET/CT imaging in MM t

119 The stability and specificity of (89)Zr-desferrioxamine (DFO)-labeled CD30-specific AC-10 antibo

120 inhibitory properties compared with those of desferrioxamine (DFO).

121 n alternative to the gold standard chelator, desferrioxamine (DFO).

122 s (such as CoCl2) or iron chelators [such as desferrioxamine (DFO)].

123 s conjugated to an octadentate derivative of desferrioxamine (DFO*) or NODAGA for (89)Zr and (64)Cu r

124 laminochroman (2-MAC; 0.3 to 2.5 microM) and desferrioxamine (DFO; 0.25 to 2 mM) reduced cell damage

125 ynthesized the immuno-PET tracer ([(89)Zr]Zr-desferrioxamine [DFO]-alpha-hCD24) and assessed target e

126 Methods: [(89)Zr]Zr-desferrioxamine [DFO]-F8 was synthesized and evaluated i

127 and 3 (DLL3) targeting antibody SC16 ((89)Zr-desferrioxamine [DFO]-SC16), we have developed a PET age

128 the IEF extract and a siderophore standard (desferrioxamine; DFO) suggested the presence of HS funct

129 othiacyanatophenyl-1-hydroxy-2-oxopiperidine-desferrioxamine (DFOcyclo*-p-Phe-NCS), and macrocyclic 1

130 amine (SNAP), a nitric oxide (NO) donor, and desferrioxamine (DFx) and cobalt chloride, mimics of cel

131 The iron chelator desferrioxamine (DFX) induces the activity of the human

132 HIF-1 inducers, cobalt chloride (CoCl2) and desferrioxamine (DFX), on HIF-1 expression and neuroprot

133 tional chelation treatment with subcutaneous desferrioxamine does not prevent excess cardiac iron dep

134 a more profound fitness penalty than loss of desferrioxamine during coculture with the yeast Saccharo

135 etase superfamily, catalyzes the key step in desferrioxamine E biosynthesis: ATP-dependent trimerisat

136 of the hydroxamate type: desferrioxamine B, desferrioxamine E, and coelichelin.

137 rescine (HSP) and is structurally related to desferrioxamine E, which is a macrocyclic trimer of N-hy

138 cells exposed to 1% O2, cobalt chloride, or desferrioxamine, each of which also increased levels of

139 Whereas hydrophilic chelator desferrioxamine exerted protection only at high and clin

140 e activity and doubling time, whereas Zn and desferrioxamine extended these recoveries and rescued Co

141 e selection of small molecule drugs, such as desferrioxamine (Fe chelator) and clioquinol (Fe, Cu, an

142 re site-specifically conjugated to maleimide-desferrioxamine for (89)Zr radiolabeling and subsequent

143 Treatment with the iron chelator desferrioxamine for 16 h prevented both translation and

144 mine for Th and a 5-fold lower affinity than desferrioxamine for Fe.

145 errichrome has a 5-fold higher affinity than desferrioxamine for Th and a 5-fold lower affinity than

146 e report the novel use of a metallo-complex, desferrioxamine-gallium (DFO-Ga) that targets P. aerugin

147 Cells that were not pretreated with desferrioxamine had Fe(III) EPR signals that were equall

148 eversed the increase in [Fe(2+)](i), whereas desferrioxamine had little effect.

149 The iron chelator desferrioxamine had no effect on DNA synthesis.

150 ssed mRNA lacked the iron-responsive element desferrioxamine had no effect upon localisation.

151 a phase I dose-escalation study with (89)Zr-desferrioxamine-IAB2M ((89)Zr-IAB2M), an anti-prostate-s

152 find that depletion of intracellular iron by desferrioxamine impairs SFT transport and iron-binding f

153 Although a controlled study of desferrioxamine in Alzheimer's disease(AD) had some prom

154 Oral deferiprone is more effective than desferrioxamine in removal of myocardial iron.

155 of >13%, which is much greater than that of desferrioxamine in this model.

156 Surprisingly, desferrioxamine increased the rate of LDL modification w

157 cells were pretreated with the iron chelator desferrioxamine, indicating a role for iron in inactivat

158 synthesis was inhibited by the iron chelator desferrioxamine, indicating that cytosolic DA and dihydr

159 Conversely, the classical iron chelator desferrioxamine induced autophagosome accumulation only

160 inepentaacetic acid and, to a lesser extent, desferrioxamine inhibited LDL oxidation when added durin

161 ee alpha-biliverdin yield in the presence of desferrioxamine is significantly increased in the "aged"

162 study, we describe the generation of (89)Zr-desferrioxamine-labeled anti-CD8 cys-diabody ((89)Zr-mal

163 Here we describe the development of (89)Zr-desferrioxamine-labeled transferrin ((89)Zr-transferrin)

164 fective mammalian cells to the iron chelator desferrioxamine leads to degradation of ferritin in the

165 HeLa cells are exposed to the iron chelator desferrioxamine, levels of SFT mRNA increase in an actin

166 derivatives along with 17 new putative acyl-desferrioxamine-like structures.

167 using cobalt chloride and the iron chelator desferrioxamine: like hypoxia, cobalt chloride and desfe

168 e (89)Zr-labeled mouse serum albumin ((89)Zr-desferrioxamine-mAlb) as a model radiotracer to assess u

169 tra- and intertumoral distribution of (89)Zr-desferrioxamine-mAlb.

170 s induced by iron can be inhibited by either desferrioxamine mesylate (an iron chelator) or succinyl

171 s shown to be independent of HIF-1alpha, and desferrioxamine mesylate (DFO) and cobalt chloride induc

172 Treatment of PC12 with the iron chelator, desferrioxamine mesylate (DFO, 50 microM for 24 h), sign

173 e method was calibrated against the marketed desferrioxamine mesylate (DFOM) siderophore and applied

174 However, as shown earlier with IRP1, both desferrioxamine mesylate and succinyl acetone will inhib

175 uli: hypoxia (strong) > iron chelation, e.g. desferrioxamine (moderate) >> transition metals, e.g. co

176 introduction of the parenteral iron chelator desferrioxamine more than 30 years ago, 50% of patients

177 methyl-1-pyrroline-1-oxide, the antioxidants desferrioxamine, nordihydroguaiaretic acid, and Amytal,

178 h intravenous infusion of the iron chelator desferrioxamine on the pulmonary circulation.

179 poB100 in primary hepatocytes was blocked by desferrioxamine or antioxidant cotreatment.

180 mbient or chemical hypoxia (upon exposure to desferrioxamine or cobalt chloride), an effect that requ

181 tes exceeded that obtained with deferiprone, desferrioxamine, or deferasirox at similar iron-binding

182 h the treatment of hypoxia, cobalt chloride, desferrioxamine, or dimethyloxalyglycine, regardless of

183 In primary human endothelial cells, hypoxia, desferrioxamine, or infection with Ad2/HIF-1alpha/VP16,

184 Desferrioxamine-p-benzyl-isothiocyanate (DFO-Bz-NCS) was

185 Desferrioxamine prevented mitochondrial ROS production a

186 e that a hydroxylase inhibitor, hypoxia, and desferrioxamine promote the functional and physical inte

187 lying hypoxia mimetic CoCl(2), iron chelator desferrioxamine, proteasome inhibitor MG-132, and 2-OG m

188 The 'Desferrioxamine Protocol' examined the effects of an 8 h

189 In the Desferrioxamine Protocol, desferrioxamine significantly

190 Our immuno-PET tracer (89)Zr-desferrioxamine-RA96 shows specific detection of MUC5AC-

191 (89)Zr-desferrioxamine-RA96 was able to detect MUC5AC with high

192 cell lines incubated with the iron chelator desferrioxamine resulted in PC7 down-regulation.

193 also known to produce the well-characterized desferrioxamine siderophore.

194 In the Desferrioxamine Protocol, desferrioxamine significantly elevated both PASP (P < 0.

195 Recovery was partial following cessation of desferrioxamine six weeks later.

196 ligate iron and also by using the chelator, desferrioxamine, that forms a redox-inactive iron comple

197 -fold increase in the level of PfIRPa in the desferrioxamine-treated cultures versus control or iron-

198 und not to alter "free" iron levels, whereas desferrioxamine treatment significantly raised these lev

199 The protective effect of desferrioxamine was mediated by the prevention of lysoso

200 ity by a hydroxylase inhibitor, hypoxia, and desferrioxamine was severely blocked by the adenoviral o

201 so demonstrate responses to both hypoxia and desferrioxamine which are independent of HIF-1 beta and

202 Desferrioxamine, which stabilizes HIF1/2alpha, did not a